Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes

M. Pette, D. F. Pette, P. A. Muraro, E. Farnon, R. Martin, H. F. McFarland

Research output: Contribution to journalArticle

Abstract

Interferon-β (IFN-β) has beneficial effects on the frequency and severity of relapses, as well as on disease progression in patients suffering from relapsing-remitting MS. Its mode of action, however, is not completely understood. Previous studies on T-lymphocyte bulk cultures and T-lymphocyte lines with specificity for different antigens suggested that the drug might partially act via suppression of T-cell proliferation and secretion of proinflammatory cytokines like interferon-γ (IFN-γ) and/or tumor necrosis factor-α (TNF-α). In this study we investigated the effects of human recombinant IFN-β(1b) on proliferation, interleukin 2 (IL-2) receptor (IL- 2R) α-chain upregulation, and cytokine and chemokine secretion of myelin basic protein-reactive, MS patient-derived T-cell clones secreting T-helper type 1 (Th1) cytokines. IFN-β partially suppressed both antigen- and IL-2- driven proliferation of these cells without affecting the expression of either IL-2 or IL-2R α-chain. There was no inhibitory effect on the secretion of IFN-γ, TNF-α, and macrophage inflammatory protein (MIP)-1α, but release was rather slightly enhanced. In conclusion, while IFN-β does reduce proliferation of Th1-like, MBP-specific T cells in vitro, the drug does not result in overall dysfunction of these cells. Therefore, the effect of IFN-β on MS may not depend on a primary inhibition of potentially encephalitogenic T lymphocytes.

Original languageEnglish (US)
Pages (from-to)385-392
Number of pages8
JournalNeurology
Volume49
Issue number2
StatePublished - Aug 1997
Externally publishedYes

Fingerprint

Myelin Basic Protein
Helper-Inducer T-Lymphocytes
Interferons
Cytokines
T-Lymphocytes
Interleukin-2
Tumor Necrosis Factor-alpha
Cell Proliferation
Macrophage Inflammatory Proteins
Antigens
Interleukin-2 Receptors
Chemokines
Pharmaceutical Preparations
Disease Progression
Up-Regulation
Clone Cells
Recurrence

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Pette, M., Pette, D. F., Muraro, P. A., Farnon, E., Martin, R., & McFarland, H. F. (1997). Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology, 49(2), 385-392.

Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. / Pette, M.; Pette, D. F.; Muraro, P. A.; Farnon, E.; Martin, R.; McFarland, H. F.

In: Neurology, Vol. 49, No. 2, 08.1997, p. 385-392.

Research output: Contribution to journalArticle

Pette, M, Pette, DF, Muraro, PA, Farnon, E, Martin, R & McFarland, HF 1997, 'Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes', Neurology, vol. 49, no. 2, pp. 385-392.
Pette, M. ; Pette, D. F. ; Muraro, P. A. ; Farnon, E. ; Martin, R. ; McFarland, H. F. / Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. In: Neurology. 1997 ; Vol. 49, No. 2. pp. 385-392.
@article{81a9b90c24104ce1b3a49e7c6b98c79a,
title = "Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes",
abstract = "Interferon-β (IFN-β) has beneficial effects on the frequency and severity of relapses, as well as on disease progression in patients suffering from relapsing-remitting MS. Its mode of action, however, is not completely understood. Previous studies on T-lymphocyte bulk cultures and T-lymphocyte lines with specificity for different antigens suggested that the drug might partially act via suppression of T-cell proliferation and secretion of proinflammatory cytokines like interferon-γ (IFN-γ) and/or tumor necrosis factor-α (TNF-α). In this study we investigated the effects of human recombinant IFN-β(1b) on proliferation, interleukin 2 (IL-2) receptor (IL- 2R) α-chain upregulation, and cytokine and chemokine secretion of myelin basic protein-reactive, MS patient-derived T-cell clones secreting T-helper type 1 (Th1) cytokines. IFN-β partially suppressed both antigen- and IL-2- driven proliferation of these cells without affecting the expression of either IL-2 or IL-2R α-chain. There was no inhibitory effect on the secretion of IFN-γ, TNF-α, and macrophage inflammatory protein (MIP)-1α, but release was rather slightly enhanced. In conclusion, while IFN-β does reduce proliferation of Th1-like, MBP-specific T cells in vitro, the drug does not result in overall dysfunction of these cells. Therefore, the effect of IFN-β on MS may not depend on a primary inhibition of potentially encephalitogenic T lymphocytes.",
author = "M. Pette and Pette, {D. F.} and Muraro, {P. A.} and E. Farnon and R. Martin and McFarland, {H. F.}",
year = "1997",
month = "8",
language = "English (US)",
volume = "49",
pages = "385--392",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes

AU - Pette, M.

AU - Pette, D. F.

AU - Muraro, P. A.

AU - Farnon, E.

AU - Martin, R.

AU - McFarland, H. F.

PY - 1997/8

Y1 - 1997/8

N2 - Interferon-β (IFN-β) has beneficial effects on the frequency and severity of relapses, as well as on disease progression in patients suffering from relapsing-remitting MS. Its mode of action, however, is not completely understood. Previous studies on T-lymphocyte bulk cultures and T-lymphocyte lines with specificity for different antigens suggested that the drug might partially act via suppression of T-cell proliferation and secretion of proinflammatory cytokines like interferon-γ (IFN-γ) and/or tumor necrosis factor-α (TNF-α). In this study we investigated the effects of human recombinant IFN-β(1b) on proliferation, interleukin 2 (IL-2) receptor (IL- 2R) α-chain upregulation, and cytokine and chemokine secretion of myelin basic protein-reactive, MS patient-derived T-cell clones secreting T-helper type 1 (Th1) cytokines. IFN-β partially suppressed both antigen- and IL-2- driven proliferation of these cells without affecting the expression of either IL-2 or IL-2R α-chain. There was no inhibitory effect on the secretion of IFN-γ, TNF-α, and macrophage inflammatory protein (MIP)-1α, but release was rather slightly enhanced. In conclusion, while IFN-β does reduce proliferation of Th1-like, MBP-specific T cells in vitro, the drug does not result in overall dysfunction of these cells. Therefore, the effect of IFN-β on MS may not depend on a primary inhibition of potentially encephalitogenic T lymphocytes.

AB - Interferon-β (IFN-β) has beneficial effects on the frequency and severity of relapses, as well as on disease progression in patients suffering from relapsing-remitting MS. Its mode of action, however, is not completely understood. Previous studies on T-lymphocyte bulk cultures and T-lymphocyte lines with specificity for different antigens suggested that the drug might partially act via suppression of T-cell proliferation and secretion of proinflammatory cytokines like interferon-γ (IFN-γ) and/or tumor necrosis factor-α (TNF-α). In this study we investigated the effects of human recombinant IFN-β(1b) on proliferation, interleukin 2 (IL-2) receptor (IL- 2R) α-chain upregulation, and cytokine and chemokine secretion of myelin basic protein-reactive, MS patient-derived T-cell clones secreting T-helper type 1 (Th1) cytokines. IFN-β partially suppressed both antigen- and IL-2- driven proliferation of these cells without affecting the expression of either IL-2 or IL-2R α-chain. There was no inhibitory effect on the secretion of IFN-γ, TNF-α, and macrophage inflammatory protein (MIP)-1α, but release was rather slightly enhanced. In conclusion, while IFN-β does reduce proliferation of Th1-like, MBP-specific T cells in vitro, the drug does not result in overall dysfunction of these cells. Therefore, the effect of IFN-β on MS may not depend on a primary inhibition of potentially encephalitogenic T lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=0030864154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030864154&partnerID=8YFLogxK

M3 - Article

C2 - 9270566

AN - SCOPUS:0030864154

VL - 49

SP - 385

EP - 392

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -